Although the frequency of developing breast and ovarian cancer in individuals harboring mutations in the BRCA2 gene is lower than in individuals harboring BRCA1 mutations, BRCA2-deficient patients have a 20-fold increased risk of developing prostate cancer and about 10-fold increased risk to pancreatic and other form of tumors like medulloblastomas and gliomas (Roy et al., 2012). The gene discussed is BRCA2; the disease is medulloblastoma.